Company MorphoSys Xetra

Equities

MOR

DE0006632003

Delayed Xetra 11:36:08 2024-08-02 EDT 5-day change 1st Jan Change
67.25 EUR -0.66% Intraday chart for MorphoSys -.--% -

Business description: MorphoSys

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Number of employees: 446

Sales by Activity: MorphoSys

Fiscal Period: December 2019 (EUR) 2020 (EUR) 2021 (EUR) 2022 (EUR) 2023 (EUR)

Partnered Discovery

37.47M 49.07M - - -

Proprietary Development

34.29M 279M - - -

Geographical breakdown of sales: MorphoSys

Fiscal Period: December 2019 (EUR) 2020 (EUR) 2021 (EUR) 2022 (EUR) 2023 (EUR)

USA

- - - - 211M

Europe (Excluding Germany)

- - - - 26.79M

Asia

- - - - 8K

USA and Canada

32.29M 319M 156M 249M -

Germany

145K - - - -

Europe and Asia

39.32M 8.64M 23.33M 29.34M -

Company details: MorphoSys

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27 0

http://www.morphosys.de
address MorphoSys(MOR)

Sector

This company's sector is not yet available
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB